215 related articles for article (PubMed ID: 9359022)
1. Systemic adverse effects of topical ophthalmic agents. Implications for older patients.
Diamond JP
Drugs Aging; 1997 Nov; 11(5):352-60. PubMed ID: 9359022
[TBL] [Abstract][Full Text] [Related]
2. Systemic adverse effects of topical ocular treatments.
Labetoulle M; Frau E; Le Jeunne C
Presse Med; 2005 Apr; 34(8):589-95. PubMed ID: 15962500
[TBL] [Abstract][Full Text] [Related]
3. Systemic effects of topical ophthalmic medications.
Selvin BL
South Med J; 1983 Mar; 76(3):349-58. PubMed ID: 6131541
[TBL] [Abstract][Full Text] [Related]
4. [New aspects on systemic adverse effects of ocular drugs].
Uusitalo H; Salminen L
Duodecim; 1998; 114(3):287-92. PubMed ID: 10895504
[No Abstract] [Full Text] [Related]
5. Systemic drug interactions with topical glaucoma medications.
Gerber SL; Cantor LB; Brater DC
Surv Ophthalmol; 1990; 35(3):205-18. PubMed ID: 1980380
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension.
Han JA; Frishman WH; Wu Sun S; Palmiero PM; Petrillo R
Cardiol Rev; 2008; 16(2):95-108. PubMed ID: 18281912
[TBL] [Abstract][Full Text] [Related]
7. Depression and topical ophthalmic beta adrenergic blockade.
Bourgeois JA
J Am Optom Assoc; 1991 May; 62(5):403-6. PubMed ID: 1687576
[TBL] [Abstract][Full Text] [Related]
8. [Complications of local pharmacotherapy in ophthalmology].
Mozherenkov VP; Ukhaneva GL
Vestn Oftalmol; 1985; 101(1):62-5. PubMed ID: 2858932
[No Abstract] [Full Text] [Related]
9. Cardiac safety of ophthalmic timolol.
Mäenpää J; Pelkonen O
Expert Opin Drug Saf; 2016 Nov; 15(11):1549-1561. PubMed ID: 27534869
[TBL] [Abstract][Full Text] [Related]
10. Ophthalmic drugs.
Kersten RC
Prim Care; 1982 Dec; 9(4):743-56. PubMed ID: 6131464
[TBL] [Abstract][Full Text] [Related]
11. Ophthalmic medications, glaucoma, and the surgical patient.
Kelsey M
J Post Anesth Nurs; 1992 Oct; 7(5):312-6. PubMed ID: 1357166
[TBL] [Abstract][Full Text] [Related]
12. Side effects of glaucoma medications.
Detry-Morel M
Bull Soc Belge Ophtalmol; 2006; (299):27-40. PubMed ID: 16681086
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of adverse events in self-reported sulfa-allergic patients using topical carbonic anhydrase inhibitors.
Guedes GB; Karan A; Mayer HR; Shields MB
J Ocul Pharmacol Ther; 2013 Jun; 29(5):456-61. PubMed ID: 23445203
[TBL] [Abstract][Full Text] [Related]
14. Topical ophthalmic medications: what potential for systemic side effects and interactions with other medications?
Goldberg I; Moloney G; McCluskey P
Med J Aust; 2008 Oct; 189(7):356-7. PubMed ID: 18837675
[TBL] [Abstract][Full Text] [Related]
15. The safety of topical beta-blockers in glaucoma treatment.
Goldberg I
Med J Aust; 1996 Apr; 164(8):498-9. PubMed ID: 8614346
[TBL] [Abstract][Full Text] [Related]
16. Resting pulse rates in a glaucoma clinic: the effect of topical and systemic beta-blocker usage.
Tattersall C; Vernon S; Singh R
Eye (Lond); 2006 Feb; 20(2):221-5. PubMed ID: 15803169
[TBL] [Abstract][Full Text] [Related]
17. Do selective topical beta antagonists for glaucoma have respiratory side effects?
Kirwan JF; Nightingale JA; Bunce C; Wormald R
Br J Ophthalmol; 2004 Feb; 88(2):196-8. PubMed ID: 14736772
[TBL] [Abstract][Full Text] [Related]
18. Co-prescribing of topical and systemic beta-blockers in patients with glaucoma: a quality use of medicine issue in Australian practice.
Goldberg I; Adena MA
Clin Exp Ophthalmol; 2007 Nov; 35(8):700-5. PubMed ID: 17997771
[TBL] [Abstract][Full Text] [Related]
19. Topical glaucoma medications and cardiovascular risk in the elderly.
Monane M; Bohn RL; Gurwitz JH; Glynn RJ; Choodnovskiy I; Avorn J
Clin Pharmacol Ther; 1994 Jan; 55(1):76-83. PubMed ID: 7905370
[TBL] [Abstract][Full Text] [Related]
20. The unwanted ocular effects from topical ophthalmic drugs. Their occurrence, avoidance and reversal.
Lyle WM; Hopkins GA
J Am Optom Assoc; 1977 Dec; 48(12):1519-23. PubMed ID: 599247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
